Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
NASDAQ:EDIT
Price:
6.12 USD
7.75%
Updated:
May 15, 2024
Editas Medicine Inc
Depreciation & Amortization
|
Editas Medicine Inc
Depreciation & Amortization Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Depreciation & Amortization Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Editas Medicine Inc
NASDAQ:EDIT
|
Depreciation & Amortization
$5.9m
|
CAGR 3-Years
11%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Depreciation & Amortization
$8.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
38%
|
CAGR 10-Years
26%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Depreciation & Amortization
$2.7B
|
CAGR 3-Years
19%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Depreciation & Amortization
$4.6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
18%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Depreciation & Amortization
$181.3m
|
CAGR 3-Years
18%
|
CAGR 5-Years
20%
|
CAGR 10-Years
14%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Depreciation & Amortization
$435.6m
|
CAGR 3-Years
21%
|
CAGR 5-Years
22%
|
CAGR 10-Years
26%
|
See Also
What is Editas Medicine Inc's Depreciation & Amortization?
Depreciation & Amortization
5.9m
USD
5.9m
USD
Based on the financial report for Mar 31, 2024, Editas Medicine Inc's Depreciation & Amortization amounts to 5.9m USD.
What is Editas Medicine Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
14%
14%
Over the last year, the Depreciation & Amortization growth was -6%. The average annual Depreciation & Amortization growth rates for Editas Medicine Inc have been 11% over the past three years , 14% over the past five years .
You don't have any saved screeners yet
